Immunohistochemical evaluation of p16INK4A, E-Cadherin, and cyclin D1 expression in melanoma and spitz tumors

American Journal of Clinical Pathology

Volumn 133, Issue 3, 2010, Pages 370-379

  George, Evan ^a   Polissar, Nayak L ^b   Wick, Mark ^c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Mountain Whisper Light Statistical Consulting   (United States)

^c UNIVERSITY OF VIRGINIA MEDICAL CENTER   (United States)

Author keywords

Cyclin D1; E cadherin; Immunohistochemistry; Large spindle and epithelioid nevus; Melanoma; P16; Spitz nevus; Spitz tumor

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 2A; FORMALDEHYDE; UVOMORULIN; CADHERIN;

ADOLESCENT; ADULT; ARTICLE; CELL CYCLE PROGRESSION; CHILD; CONTROLLED STUDY; CYTOPLASM; DERMIS; EPIDERMIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPEROXIDASE STAINING; IMMUNOPHENOTYPING; IMMUNOREACTIVITY; JUVENILE MELANOMA; MAJOR CLINICAL STUDY; MALE; MELANOCYTE; MELANOMA; NEVUS; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; SCHOOL CHILD; AGED; CHI SQUARE DISTRIBUTION; DIFFERENTIAL DIAGNOSIS; METABOLISM; MIDDLE AGED; SKIN TUMOR;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CADHERINS; CHI-SQUARE DISTRIBUTION; CHILD; CHILD, PRESCHOOL; CYCLIN D1; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MELANOMA; MIDDLE AGED; NEVUS, EPITHELIOID AND SPINDLE CELL; SKIN NEOPLASMS;

EID: 77949366039     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/AJCP52YVYCTLUOPI     Document Type: Article

References (13)

1. Barnhill RL, Busam KJ. Spitz nevus and variants. In: Barnhill RL, Piepkorn M, Busam KJ, eds. Pathology of Melanocytic Nevi and Malignant Melanoma. New York, NY: Springer-Verlag; 2004:148-198.
2. Barnhill RL. Malignant melanoma. In: Barnhill RL, Piepkorn M, Busam KJ, eds. Pathology of Melanocytic Nevi and Malignant Melanoma. New York, NY: Springer-Verlag; 2004:238-356.
3. McDermott NC, Hayes DP, al-Sader MH, et al. Identification of vertical growth phase in malignant melanoma: a study of interobserver agreement. Am J Clin Pathol. 1998;110:753-757.
4. Sayadi H, Fitzgibbon JF, Ritter JH, et al. Azure-B as a counterstain in the immunohistological evaluation of heavily pigmented nevomelanocytic lesions. Appl Immunohistochem. 1995;3:268-271.
5. Kligora CJ, Fair KP, Clem MS, et al. A comparison of melanin bleaching and azure blue counterstaining in the immunohistochemical diagnosis of malignant melanoma. Mod Pathol. 1999;12:1143-1147.
6. Krengel S, Groteluschen F, Bartsch S, et al. Cadherin expression pattern in melanocytic tumors more likely depends on the melanocyte environment than on tumor cell progression. J Cutan Pathol. 2004;31:1-7. (Pubitemid 38130269)
7. Nagasaka T, Lai R, Medeiros LJ, et al. Cyclin D1 expression in Spitz nevi: an immunohistochemical study. Am J Dermatopathol. 1999;21:115-120. (Pubitemid 29162868)
8. Chin L, Garraway LA, Fisher DE. Malignant melanoma: genetics and therapeutics in the genomic era. Genes Dev. 2006;20:2149-2182. (Pubitemid 44244518)
9. Sparrow LE, Eldon MJ, English DR, et al. p16 and p21WAF1 protein expression in melanocytic tumors by immunohistochemistry. Am J Dermatopathol. 1998;20:255-261.
10. Bachmann IM, Straume O, Puntervoll HE, et al. Importance of P-cadherin, beta-catenin, and Wnt5a/frizzled for progression of melanocytic tumors and prognosis in cutaneous melanoma. Clin Cancer Res. 2005;11:8606-8614. (Pubitemid 43005907)
11. Sanders D, Blessing K, Hassan GA, et al. Alterations in cadherin and catenin expression during the biological progression of melanocytic tumours. Mol Pathol. 1999;52:151-157.
12. Silye R, Karayiannakis AJ, Syrigos KN, et al. E-cadherin/catenin complex in benign and malignant melanocytic lesions. J Pathol. 1998;186:350-355.
13. Tucci MG, Lucarini G, Brancorsini D, et al. Involvement of E-cadherin, beta-catenin, Cdc42 and CXCR4 in the progression and prognosis of cutaneous melanoma. Br J Dermatol. 2007;157:1212-1216.